Micromet To Present Clinical Update For BiTE Antibody MT103/MEDI-538 At The International Conference On Malignant Lymphomas
Jun 1st 2008Drug InformationLymphoma / Leukemia
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the company will provide an update on the phase 1 clinical trial underway for its BiTE(R) antibody MT103/MEDI-538 at the 10th International Conference on Malignant Lymphomas, taking place June 4-7 in Lugano, Switzerland.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
